Source link : https://www.newshealth.biz/health-news/patisiran-shows-long-term-benefit-in-hereditary-attr-with-polyneuropathy/
Patisiran continued to demonstrate benefit in hATTR with polyneuropathy at 5 years. Measures of disability, polyneuropathy, and quality of life showed modest changes. This is the longest study of an RNA interference therapeutic for any disease. Long-term treatment with patisiran (Onpattro) led to modest changes for people with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy, data […]
Author : News Health
Publish date : 2025-01-15 17:31:45
Copyright for syndicated content belongs to the linked Source.